Improving Outcome in Schizophrenia: The Potential Importance of EPS and Neuroleptic Dysphoria

References

• Van Os 3, Wright P, Murray RM: Follow-up studies of schizophrenia. 1: Natural history and non-psychopathological predictors of outcome. Eur Psychiatry 1997; 12\(Suppl 5):327s–341s
   Google Scholar
• Kissling W, Fleischhacker WW: Optimising prophylactic treat-ment of schizophrenia by means of treatment standards and compliance improvement. Pharmacopsychiatry 1992; 25:69–71
   Google Scholar
• Kissling W, Leucht S: Results of treatment of schizophrenia: Is the glass half full or half empty? Int Clin Psychopharmacol 1999; 14(Suppl 3):S11–S14
   Google Scholar
• Helgason L: Twenty years' follow-up of first psychiatric pre-sentation for schizophrenia: What could have been prevented? Acta Psychiatr Scand 1990; 81:231–235
   Google Scholar
• Bebbington PE: The content and context of compliance. Int Clin Psychopharmacol 1995; 9(Suppl 5):41–50
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56:241–247
   PubMed Web of Science ®Google Scholar
• Green JH: Frequent rehospitalization and noncompliance with treatment. Hosp Commun Psychiatry 1988; 39:963–966
   PubMedGoogle Scholar
• Caton CL, Koh SP, Fleiss JL, Barrow S, Goldstein JM: Rehos-pitalization in chronic schizophrenia. J Nerv Ment Dis 1985; 173:139–148
   PubMed Web of Science ®Google Scholar
• Corrigan PW, Liberman RP, Engel JD: From noncompliance to collaboration in the treatment of schizophrenia. Hosp Com-munity Psychiatry 1990; 41:1203–1211
   PubMedGoogle Scholar
• Fenton WS, Blyler CR, Heinssen RK: Determinants of medica-tion compliance in schizophrenia: Empirical and clinical find-ings. Schizophr Bull 1997; 23:637–651
   PubMed Web of Science ®Google Scholar
• Kampman 0, Lehtinen K: Compliance in psychoses. Acta Psy-chiatr Scand 1999; 100:167–175
   Web of Science ®Google Scholar
• Awad AG, Hogan TP: Subjective response to neuroleptics and the quality of life: Implications for treatment outcome. Acta Psychiatr Scand Suppl 1994; 380:27–32
   Google Scholar
• Weiden P, Zygmunt A: Which side-effects really matter to our patients? Approaches Schizophr Commun 1999; 2:5–11
   Google Scholar
• Gerlach J, Korsgaard S. Clemmesen P, Lauersen AM, Magelund G, Noring U, Povlsen UJ, Bech P, Casey DE: The St. Hans Rating Scale for extrapyramidal syndromes: Reli-ability and validity. Acta Psychiatr Scand 1993; 87:244–252
   Google Scholar
• Haase H-J, Janssen PAJ: The Action of Neuroleptic Drugs. Amsterdam: North-Holland; 1965
   Google Scholar
• Hummer M, Fleischhacker WW: Compliance and outcome in patients treated with antipsychotics. The impact of extrapyra-midal syndromes. CNS Drugs 1996; 5\(Supp11):13–20
   Google Scholar
• King DJ, Burke M, Lucas RA: Antipsychotic drug-induced dysphoria. Br J Psychiatry 1995; 167:480–482
   Google Scholar
• Bruun RD: Dysphoric phenomena associated with haloperidol treatment of Tourette syndrome. In: Friedhoff Al, Chase TN, eds. Gilles de la Tourette Syndrome. New York: Raven Press; 1982:433–436
   Google Scholar
• Larsen EB, Gerlach J: Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996; 93:381–388
   PubMed Web of Science ®Google Scholar
• Finn SE, Bailey JM, Schultz RT, Faber R: Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med 1990; 20:843–848
   PubMed Web of Science ®Google Scholar
• Van Putten T: Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31:67–72
   PubMed Web of Science ®Google Scholar
• Buchanan A: A two-year prospective study of treatment com-pliance in patients with schizophrenia. Psychol Med 1992; 22:787–797
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Meise U, Gunther V, Kurz M: Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatr Scand Suppl 1994; 382:11–15
   PubMedGoogle Scholar
• Garavan J, Browne S, Gervin M, Lane A, Larkin C, O'Callaghan E: Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective re-sponse to neuroleptics; attitudes to medication and insight. Compr Psychiatry 1998; 39:215–219
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Mann JJ, Dixon L, Haas G, DeChillo N, Frances AJ: Is neuroleptic dysphoria a healthy response? Compr Psy-chiatry 1989; 30:546–552
   PubMed Web of Science ®Google Scholar
• Van Putten T, May PR, Marder SR: Response to antipsychotic medication: The doctor's and the consumer's view. Am J Psy-chiatry 1984; 141:16–19
   PubMed Web of Science ®Google Scholar
• Simpson GM, Kunz-Bartholini E: Relationship of individual tolerance, behavior and phenothiazine produced extrapyrami-dal system disturbance. Dis Nerv Syst 1968; 29:269–274
   PubMedGoogle Scholar
• Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, Weiden P: Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993; 29:309–314
   PubMedGoogle Scholar
• Levinson DF, Simpson GM, Singh H, Yadalam K, JaM A, Stephanos MJ, Silver P: Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 1990; 47:761–768
   Google Scholar
• Newcomer JVV, Miller LS, Faustman WO, Wetzel MW, Vogler GP, Csernansky JG: Correlations between akathisia and resid-ual psychopathology: A by-product of neuroleptic-induced dysphoria. Br J Psychiatry 1994; 164:834–838
   Google Scholar
• Van Putten T, May PR, Marder SR, Wittmann LA: Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38:187–190
   PubMed Web of Science ®Google Scholar
• Van Putten T, May PR: Subjective response as a predictor of outcome in pharmacotherapy: The consumer has a point. Arch Gen Psychiatry 1978; 35:477–480
   PubMed Web of Science ®Google Scholar
• Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HO, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8–19
   PubMed Web of Science ®Google Scholar
• Rupp A, Keith Si: The costs of schizophrenia. Assessing the burden. Psychiatr Clin North Am 1993; 16:413–423
   PubMed Web of Science ®Google Scholar
• Rice DP: The economic impact of schizophrenia. J Clin Psy-chiatry 1999; 60\(Supp11):4–6
   Google Scholar
• Davies LM, Drummond MF: Economics and schizophrenia: The real cost. Br J Psychiatry 1994; 165(Suppl 25):18–21
   Google Scholar
• Goeree R, O'Brien BJ, Goering P, Blackhouse G, Agro K, Rhodes A, Watson J: The economic burden of schizophrenia in Canada. Can J Psychiatry 1999; 44:464–472
   PubMed Web of Science ®Google Scholar
• Guest JF, Cookson RF: Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999; 15:597–610
   Google Scholar
• Davies LM, Drummond MF: The economic burden of schizophrenia. Psychol Bull 1990; 14:522–525
   Google Scholar
• Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophr Bull 1995; 21:419–429
   PubMed Web of Science ®Google Scholar
• Kopala LC: Spontaneous and drug-induced movement dis-orders in schizophrenia. Acta Psychiatr Scand Suppl 1996; 389:12–17
   Google Scholar
• Cortese L, Pourcher-Bouchard E, Williams R: Assessment and management of antipsychotic-induced adverse events. Can J Psychiatry 1998; 43\(Suppl 1):15S–20S
   Google Scholar
• Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf IA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329:162–167
   PubMed Web of Science ®Google Scholar
• Jibson MD, Tandon R: New atypical antipsychotic medica-tions. J Psychiatr Res 1998; 32:215–228
   PubMed Web of Science ®Google Scholar
• Owens DG: Extrapyramidal side effects and tolerability of risperidone: A review. J Clin Psychiatry 1994; 55(Suppl):29–35
   Google Scholar
• Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double- blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166:712–726; discussion 727-733
   PubMed Web of Science ®Google Scholar
• Bhana N, Foster RH, Olney R, Plosker GL: Olanzapine: An updated review of its use in the management of schizophrenia. Drugs 2001; 61:111–161
   PubMed Web of Science ®Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20:491–505
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG: Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophre-nia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42:233–246
   Google Scholar
• Peuskens J, Link CG: A comparison of quetiapine and chlor-promazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96:265–273
   PubMed Web of Science ®Google Scholar
• Copolov DL, Link CG, Kowalcyk B: A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med 2000; 30:95–105
   PubMed Web of Science ®Google Scholar
• Mullen J, Jibson MD, Sweitzer D: A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperid one in outpatients with schizophrenia and other psychotic disor-ders: The quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001; 23:1839–1854
   PubMed Web of Science ®Google Scholar
• Brecher M, Rak IW, Westhead EK, Jones AM: The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia. Int J Psych Clin Pract 2000:4:287–292
   PubMed Web of Science ®Google Scholar
• Hellewell JSE, Kalali AH, Langham SJ, McKellar J, Awad AG: Patient satisfaction and acceptability of long-term treatment with quetiapine. lot J Psych Clin Pract 1999; 3:105–113
   PubMedGoogle Scholar
• Collaborative Working Group on Clinical Trial Evaluations: Treatment of special populations with the atypical antipsy-chotics. J Clin Psych 1998; 59(Suppl 12):46–52
   Google Scholar
• Gregory C, McKenna P: Pharmacological management of schizophrenia in older patients. Drugs Aging 1994; 5:254–262
   Google Scholar
• Eastham JH, Jeste DV: Treatment of schizophrenia and delu-sional disorder in the elderly. Eur Arch Psychiatry Clin Neu-rosci 1997; 247:209–218
   PubMed Web of Science ®Google Scholar
• Avorn J, Monane M, Everitt DE, Beers MH, Fields D: Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication. Arch Int Med 1994; 154:1113–1117
   Google Scholar
• Zayas EM, Grossberg GT: The treatment of psychosis in late life. J Clin Psychiatry 1998; 59\(Suppl 1):5–10; discussion 11–12
   Google Scholar
• Tariot PN: The older patient: The ongoing challenge of efficacy and tolerability. J Clin Psychiatry 1999; 60(Suppl 23):29–33
   Google Scholar
• Mamo DC, Sweet RA, Keshavan MS: Managing anti psychotic-induced parkinsonism. Drug Saf 1999; 20:269–275
   PubMed Web of Science ®Google Scholar
• Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM: Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. Am J Psychiatry 1998; 155:1521–1528
   PubMed Web of Science ®Google Scholar
• Findling RL: Paediatric psychopharmacology: Closing the gap between science and practice. Expert Opin Pharmacother 2001; 2:523–525
   PubMedGoogle Scholar
• Lewis R: Typical and atypical antipsychotics in adolescent schizophrenia: Efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 1998; 43:596–604
   PubMed Web of Science ®Google Scholar
• Aguilar EJ, Keshavan MS, Martinez-Quiles MD, Hernandez J, Gomez-Beneyto M, Schooler NR: Predictors of acute dysto-nia in first-episode psychotic patients. Am J Psychiatry 1994; 151:1819–1821
   PubMed Web of Science ®Google Scholar
• Hriso E, Kuhn T, Masdeu JC, Grundman M: Extrapyrami-dal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 1991; 148:1558–1561
   PubMed Web of Science ®Google Scholar
• Itoh K, Mehraein P, Weis S: Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol (Berl) 2000; 99:376–384
   PubMed Web of Science ®Google Scholar
• Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW: Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000; 22:1068–1084
   PubMed Web of Science ®Google Scholar
• McConville B, Wong J, Yeh C, Wilkinson L, Chaney R, Foster K, Sorter M, Friedman L, Browne K: Safety, tolerabil-ity and clinical effectiveness of quetiapine in adolescents with selected psychotic disorders: A long-term, open-label study. J Child Adolesc Psychopharmacol 2000; 10:254–255
   Google Scholar